Response Genetics, Inc.  

(Public, NASDAQ:RGDX)   Watch this stock  
Find more results for Sam Chawla�
-0.020 (-2.54%)
Real-time:   9:58AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.77 - 0.83
52 week 0.61 - 2.45
Open 0.81
Vol / Avg. 11,190.00/93,783.00
Mkt cap 29.83M
P/E     -
Div/yield     -
EPS -0.60
Shares 38.73M
Beta 0.69
Inst. own 44%
Aug 14, 2014
Q2 2014 Response Genetics Inc Earnings Call
Aug 14, 2014
Q2 2014 Response Genetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -89.97% -40.50%
Operating margin -89.29% -40.13%
EBITD margin - -36.93%
Return on average assets -86.72% -46.30%
Return on average equity -343.10% -307.49%
Employees 109 -
CDP Score - -


6th Floor, 1640 Marengo St.
United States - Map
+1-323-2243900 (Phone)
+1-323-2243096 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Response Genetics, Inc. is a life sciences company engaged in the research and development of clinical diagnostic tests for cancer. The Company�s technologies enable it to reliably and consistently extract ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) from tumor specimens that are stored as formalin-fixed and paraffin-embedded (FFPE) specimens and thereby to analyze genetic information contained in these tissues. The Company�s technologies also enable us to use the FFPE patient biopsies for the development of diagnostic tests. The Company provide tests for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric and gastroesophageal cancer (GE), melanoma and thyroid cancer, and breast cancer patients� tumor tissue specimens through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid and ResponseDX: Breast test.

Officers and directors

Thomas A. Bologna Chairman of the Board, Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Kevin R. Harris Chief Financial Officer, Vice President
Age: 45
Bio & Compensation  - Reuters
Stephanie H. Astrow Ph.D. Vice President - Research & Development
Age: 52
Bio & Compensation  - Reuters
Adanech Getachew General Counsel
Age: 37
Bio & Compensation  - Reuters
Kirk K. Calhoun Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Michael Serruya Director
Age: 49
Bio & Compensation  - Reuters
Sam Chawla Independent Director
Age: 39
Bio & Compensation  - Reuters
David R. Schreiber Independent Director
Bio & Compensation  - Reuters
Richard A. Van den Broek Independent Director
Age: 48
Bio & Compensation  - Reuters